Restenosis Inhibition and Re-differentiation of TGFβ/Smad3-activated Smooth Muscle Cells by Resveratrol

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Zhu, Yichen ^a,b   Takayama, Toshio ^a   Wang, Bowen ^a   Kent, Alycia ^a   Zhang, Mengxue ^a   Binder, Bernard Y K ^a   Urabe, Go ^a   Shi, Yatao ^c   Direnzo, Daniel ^a   Goel, Shakti A ^a   Zhou, Yifan ^a   Little, Christopher ^a   Roenneburg, Drew A ^a   Shi, Xu Dong ^a   Li, Lingjun ^c,d   Murphy, William L ^a   Kent, K Craig ^a   Ke, Jianjuan ^e   Guo, Lian Wang ^a  

^a University of Wisconsin Health   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d TIANJIN UNIVERSITY   (China)

^e WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; MADH3 PROTEIN, RAT; RESVERATROL; SMAD3 PROTEIN; STILBENE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIOXIDANTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CORONARY RESTENOSIS; GENE EXPRESSION REGULATION; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; STILBENES; TRANSFORMING GROWTH FACTOR BETA;

EID: 85011887412     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep41916     Document Type: Article

References (47)

1. Goel, S. A., Guo, L. W., Liu, B. & Kent, K. C. Mechanisms of post-intervention arterial remodelling. Cardiovascular research 96, 363-371 (2012).
2. Ichimoto, E. et al. Mechanism of edge restenosis after sirolimus-eluting stent implantation. J Invasive Cardiol 24, 55-57 (2012).
3. Inoue, T. et al. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC. Cardiovascular interventions 4, 1057-1066 (2011).
4. Holy, E. W. et al. PI3K/p110alpha inhibition selectively interferes with arterial thrombosis and neointima formation, but not reendothelialization: potential implications for drug-eluting stent design. European heart journal 35, 808-820 (2014).
5. Guo, L. W. et al. Halofuginone stimulates adaptive remodeling and preserves re-endothelialization in balloon-injured rat carotid arteries. Circ Cardiovasc Interv 7, 594-601 (2014).
6. J, G. et al. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. Journal of cardiovascular pharmacology 47, 711-721 (2006).
7. Orozco-Sevilla, V. et al. Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery. Journal of vascular surgery 58, 1360-1365 (2013).
8. Choi, K. H. et al. Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovascular research 85, 836-844 (2010).
9. Khandelwal, A. R. et al. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. The Journal of nutrition 142, 1487-1494 (2012).
10. Zhang, J. et al. Resveratrol attenuates oxidative stress induced by balloon injury in the rat carotid artery through actions on the ERK1/2 and NF-kappa B pathway. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 31, 230-241 (2013).
11. Kim, J. W. et al. Inhibition of neointimal formation by trans-resveratrol: role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Molecular nutrition & food research 54, 1497-1505 (2010).
12. Smoliga, J. M., Baur, J. A. & Hausenblas, H. A. Resveratrol and health-a comprehensive review of human clinical trials. Molecular nutrition & food research 55, 1129-1141 (2011).
13. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C. & Beaudeux, J. L. Resveratrol bioavailability and toxicity in humans. Molecular nutrition & food research 54, 7-16 (2010).
14. Tolva, V. et al. A successful experimental model for intimal hyperplasia prevention using a resveratrol-delivering balloon. Journal of vascular surgery 63, 788-794 (2016).
15. Chaudhary, M. A. et al. Periadventitial drug delivery for the prevention of intimal hyperplasia following open surgery. Journal of controlled release: official journal of the Controlled Release Society 233, 174-180 (2016).
16. Shi, X. et al. Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis. PloS one 9, e89227 (2014).
17. Jim, J., Owens, P. L., Sanchez, L. A. & Rubin, B. G. Population-based analysis of inpatient vascular procedures and predicting future workload and implications for training. Journal of vascular surgery 55, 1394-1399, discussion 1399-1400 (2012).
18. Yu, X. et al. A rapamycin-releasing perivascular polymeric sheath produces highly effective inhibition of intimal hyperplasia. Journal of controlled release: official journal of the Controlled Release Society 191, 47-53 (2014).
19. Liu, R. et al. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation 128, 2047-2057 (2013).
20. Thompson, A. M., Martin, K. A. & Rzucidlo, E. M. Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK. PloS one 9, e85495 (2014).
21. Tsai, S. et al. TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. American journal of physiology. Heart and circulatory physiology 297, H540-549 (2009).
22. Shi, X. et al. TGF-beta/Smad3 stimulates stem cell/developmental gene expression and vascular smooth muscle cell dedifferentiation. PloS one 9, e93995 (2014).
23. Nemenoff, R. A. et al. SDF-1alpha induction in mature smooth muscle cells by inactivation of PTEN is a critical mediator of exacerbated injury-induced neointima formation. Arteriosclerosis, thrombosis, and vascular biology 31, 1300-1308 (2011).
24. Shi, X. et al. Local CXCR4 Upregulation in the Injured Arterial Wall Contributes to Intimal Hyperplasia. Stem Cells 34, 2744-2757 (2016).
25. Alexander, M. R. & Owens, G. K. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol 74, 13-40 (2012).
26. Shankman, L. S. et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nature medicine 21, 628-637 (2015).
27. Suzuki, T. et al. Kruppel-like factor 5 shows proliferation-specific roles in vascular remodeling, direct stimulation of cell growth, and inhibition of apoptosis. The Journal of biological chemistry 284, 9549-9557 (2009).
28. Dong, J. T. & Chen, C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cellular and molecular life sciences: CMLS 66, 2691-2706 (2009).
29. Wang, B. et al. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. EBioMedicine 2, 1650-1661 (2015).
30. Hao, L. et al. In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms. Scientific reports 6, 30869 (2016).
31. Hao, L., Zhong, X., Greer, T., Ye, H. & Li, L. Relative quantification of amine-containing metabolites using isobaric N, N-dimethyl leucine (DiLeu) reagents via LC-ESI-MS/MS and CE-ESI-MS/MS. The Analyst 140, 467-475 (2015).
32. Suwanabol, P. A. et al. TGF-beta and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells. American journal of physiology. Heart and circulatory physiology 302, H2211-2219 (2012).
33. DiRenzo, D. M. et al. A crosstalk between TGF-beta/Smad3 and Wnt/beta-catenin pathways promotes vascular smooth muscle cell proliferation. Cellular signalling 28, 498-505 (2016).
34. Brito, P. M. et al. Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis 205, 126-134 (2009).
35. Yoshida, T., Kaestner, K. H. & Owens, G. K. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circulation research 102, 1548-1557 (2008).
36. Goel, S. A. et al. High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation. PloS one 9, e89349 (2014).
37. Kleinedler, J. J., Foley, J. D., Orchard, E. A. & Dugas, T. R. Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. Journal of controlled release: official journal of the Controlled Release Society 159, 27-33 (2012).
38. Aires, V. et al. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Molecular nutrition & food research 57, 1170-1181 (2013).
39. Yurdagul, A. Jr. et al. Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptoralpha-dependent pathway. American journal of physiology. Heart and circulatory physiology 306, H797-806 (2014).
40. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: The in vivo evidence. Nature reviews. Drug discovery 5, 493-506 (2006).
41. Park, S. J. et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433 (2012).
42. Nwachukwu, J. C. et al. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. eLife 3, e02057 (2014).
43. Sajish, M. & Schimmel, P. A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature 519, 370-373 (2015).
44. Li, H. X. et al. Kruppel-like factor 4 promotes differentiation by transforming growth factor-beta receptor-mediated Smad and p38 MAPK signaling in vascular smooth muscle cells. The Journal of biological chemistry 285, 17846-17856 (2010).
45. Cheng, Y. et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circulation research 105, 158-166 (2009).
46. Chan, A. Y. et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. The Journal of biological chemistry 283, 24194-24201 (2008).
47. Liu, M. et al. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. The Journal of biological chemistry 285, 36387-36394 (2010).